Want to see IN:MANGALAM full AI Analyst Report?
MANGALAM Stock Chart & Stats
₹30.40
-₹1.02(-0.89%)
At close: 4:00 PM EST
₹30.40
-₹1.02(-0.89%)
Day’s Range― - ―
52-Week Range₹22.70 - ₹74.00
Previous CloseN/A
Volume15.57K
Average Volume (3M)12.40K
Market Cap
₹459.02M
Enterprise Value₹1.55B
Total Cash (Recent Filing)₹7.51M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)―
Beta0.65
Next Earnings
Nov 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.28%
Share Statistics
EPS (TTM)-24.16
Shares Outstanding15,828,248
10 Day Avg. Volume10,434
30 Day Avg. Volume12,400
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.42
Price to Sales (P/S)0.19
P/FCF Ratio-2.07
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Specialty Chemical Intermediate PlatformA focused portfolio of specialty intermediates gives Mangalam an established industrial role across pharmaceutical and chemical value chains. Serving both domestic and export customers broadens the addressable market and allows growth through volumes, product mix, and downstream derivatives.
Positive Equity And Asset BasePositive net equity and a sizable asset base provide an underlying financial foundation for ongoing operations, even after the latest downturn. This asset support can help preserve strategic flexibility and gives the company a stronger base than a balance sheet with accumulated negative equity.
Demonstrated Historical Cash GenerationThe business has previously demonstrated the ability to convert operations into positive cash flow and earnings during stronger periods. That record indicates the model can generate financial returns when demand, pricing, utilization, and costs are more favorable, supporting recovery potential over time.
Bears Say
Sharp Profitability DeteriorationThe move from modest profit to substantial net and operating losses weakens internal funding capacity and makes earnings less predictable. Persistent negative operating margins would reduce the resources available for maintenance, investment, debt service, and rebuilding customer or market momentum.
Multi-year Revenue ContractionSeveral years of declining revenue suggest the current weakness is broader than a single reporting period. Shrinking sales can reduce plant utilization and operating leverage, pressure the product mix, and make it harder for fixed costs to be absorbed while restoring sustainable profitability.
Negative And Inconsistent Cash FlowNegative operating and free cash flow means the latest business performance is consuming rather than producing funding. The history of inconsistency raises execution risk and may force greater reliance on financing, particularly when investment needs and debt obligations coincide with weak profitability.
Mangalam Drugs & Organics Ltd. News
MANGALAM FAQ
What was Mangalam Drugs & Organics Ltd.’s price range in the past 12 months?
Mangalam Drugs & Organics Ltd. lowest stock price was ₹22.70 and its highest was ₹74.00 in the past 12 months.
What is Mangalam Drugs & Organics Ltd.’s market cap?
Mangalam Drugs & Organics Ltd.’s market cap is ₹459.02M.
When is Mangalam Drugs & Organics Ltd.’s upcoming earnings report date?
Mangalam Drugs & Organics Ltd.’s upcoming earnings report date is Nov 14, 2026 which is in 39 days.
How were Mangalam Drugs & Organics Ltd.’s earnings last quarter?
Mangalam Drugs & Organics Ltd. released its earnings results on Aug 12, 2026. The company reported -₹4.826 earnings per share for the quarter.
Is Mangalam Drugs & Organics Ltd. overvalued?
According to Wall Street analysts Mangalam Drugs & Organics Ltd.’s price is currently Overvalued.
Does Mangalam Drugs & Organics Ltd. pay dividends?
Mangalam Drugs & Organics Ltd. pays a Notavailable dividend of ₹0.5 which represents an annual dividend yield of 0.28%. See more information on Mangalam Drugs & Organics Ltd. dividends here
What is Mangalam Drugs & Organics Ltd.’s EPS estimate?
Mangalam Drugs & Organics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Mangalam Drugs & Organics Ltd. have?
Mangalam Drugs & Organics Ltd. has 15,828,248 shares outstanding.
What happened to Mangalam Drugs & Organics Ltd.’s price movement after its last earnings report?
Mangalam Drugs & Organics Ltd. reported an EPS of -₹4.826 in its last earnings report. Following the earnings report the stock price went up 0.333%.
Which hedge fund is a major shareholder of Mangalam Drugs & Organics Ltd.?
Currently, no hedge funds are holding shares in IN:MANGALAM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Mangalam Drugs & Organics Ltd.
Based in Mumbai, India, Mangalam Drugs & Organics Limited, established in 1972, operates as a global pharmaceutical enterprise. The company is engaged in the production and distribution of a diverse range of medications, drugs, and associated pharmaceutical goods, serving both domestic Indian and international markets. Its offerings encompass various active pharmaceutical ingredients (APIs), chemical intermediates, specialized compounds, and impurities, which are crucial for treatments targeting conditions such as malaria, pain and inflammation, high blood pressure, and retroviral infections.
Technical Analysis
Biofil Chemicals & Pharmaceuticals Ltd.
―
Lasa Supergenerics Ltd.
―
Par Drugs and Chemicals Limited
―
Vaishali Pharma Ltd.
―
Vivimed Labs Limited
―